Literature DB >> 26025219

High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry.

Viveca Ritsinger1, Nawsad Saleh2, Bo Lagerqvist2, Anna Norhammar2.   

Abstract

BACKGROUND: Patients with diabetes mellitus have reduced longevity after acute coronary syndromes and revascularization. However, knowledge of the long-term complication rates and patterns from an everyday life setting is lacking. METHODS AND
RESULTS: Consecutive patients undergoing percutaneous coronary intervention included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) between 2006 and 2010 and with no previous revascularization were prospectively followed up for combined cardiovascular events (first of all-cause mortality, myocardial infarction, stroke, and heart failure) until December 31, 2010. The mean follow-up period was 920 days (SD, 530 days). Differences in background and procedural characteristics were adjusted for in a multivariate Cox regression model. Of 58 891 patients, mean age 67 years, 19% had diabetes mellitus; 27% of them were on diet treatment, 33% on oral glucose lowering, and 40% on insulin treatment. At admission, cardiovascular risk factors, multiple coronary vessel, and left main stem disease were more frequent in patients with diabetes mellitus and their revascularization was less often complete. The adjusted risk for combined cardiovascular events was higher in patients on insulin (hazard ratio [95% confidence interval], 1.63 [1.55-1.72]), on oral treatment (1.23 [1.15-1.31]), and on diet alone (1.21 [1.12-1.29]) compared with patients without diabetes mellitus. Insulin-treated patients ran an increased risk of restenosis (1.54 [1.39-1.71]) and stent thrombosis (1.56 [1.25-1.96]).
CONCLUSIONS: The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular diseases; cause of death; complications of diabetes mellitus; diabetes mellitus; insulin; percutaneous coronary intervention

Mesh:

Year:  2015        PMID: 26025219     DOI: 10.1161/CIRCINTERVENTIONS.114.002328

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  14 in total

Review 1.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

2.  Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Joo Myung Lee; Ki Hong Choi; Bon-Kwon Koo; Hakim-Moulay Dehbi; Joon-Hyung Doh; Chang-Wook Nam; Eun-Seok Shin; Christopher M Cook; Rasha Al-Lamee; Ricardo Petraco; Sayan Sen; Iqbal S Malik; Sukhjinder S Nijjer; Hernán Mejía-Rentería; Eduardo Alegria-Barrero; Ali Alghamdi; John Altman; Sérgio B Baptista; Ravinay Bhindi; Waldemar Bojara; Salvatore Brugaletta; Pedro Canas Silva; Carlo Di Mario; Andrejs Erglis; Robert T Gerber; Olaf Going; Tobias Härle; Farrel Hellig; Ciro Indolfi; Luc Janssens; Allen Jeremias; Rajesh K Kharbanda; Ahmed Khashaba; Yuetsu Kikuta; Florian Krackhardt; Mika Laine; Sam J Lehman; Hitoshi Matsuo; Martijin Meuwissen; Giampaolo Niccoli; Jan J Piek; Flavo Ribichini; Habib Samady; James Sapontis; Arnold H Seto; Murat Sezer; Andrew S P Sharp; Jasvindar Singh; Hiroaki Takashima; Suneel Talwar; Nobuhiro Tanaka; Kare Tang; Eric Van Belle; Niels van Royen; Hugo Vinhas; Christiaan J Vrints; Darren Walters; Hiroyoshi Yokoi; Bruce Samuels; Chris Buller; Manesh R Patel; Patrick Serruys; Javier Escaned; Justin E Davies
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

3.  Diabetes mellitus, revascularization and outcomes in elderly patients with myocardial infarction-related cardiogenic shock.

Authors:  Miquel Gual; Ariza Albert-Solé; Marí Garcaí Maárquez; Cristina Fernández; José L Bernal; Francesc Formiga; María-Isabel Barrionuevo; José C Sánchez-Salado; Victòria Lorente; Júlia Pascual; Isaac Llaó; Oriol Alegre; Angel Cequier; Javier Elola
Journal:  J Geriatr Cardiol       Date:  2020-10-28       Impact factor: 3.327

4.  Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.

Authors:  Monica Verdoia; Patrizia Pergolini; Matteo Nardin; Roberta Rolla; Lucia Barbieri; Alon Schaffer; Paolo Marino; Giorgio Bellomo; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

5.  CYP2C192 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls.

Authors:  Jenny Ruedlinger; Yalena Prado; Tomás Zambrano; Nicolás Saavedra; Braulio Bobadilla; Marcelo Potthoff; Luis Pérez; Fernando Lanas; Luis A Salazar
Journal:  Biomed Res Int       Date:  2017-07-13       Impact factor: 3.411

6.  Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.

Authors:  Thomas Nyström; Johan Bodegard; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W Eriksson
Journal:  Diabetes Obes Metab       Date:  2017-03-16       Impact factor: 6.577

Review 7.  PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Authors:  David Preiss; Marion Mafham
Journal:  Diabetologia       Date:  2016-12-26       Impact factor: 10.122

8.  Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.

Authors:  Marco Trevisan; Edouard L Fu; Karolina Szummer; Anna Norhammar; Pia Lundman; Christoph Wanner; Arvid Sjölander; Tomas Jernberg; Juan Jesus Carrero
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-03-15

9.  Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.

Authors:  Remzi Anadol; Katharina Schnitzler; Liv Lorenz; Melissa Weissner; Helen Ullrich; Alberto Polimeni; Thomas Münzel; Tommaso Gori
Journal:  BMC Cardiovasc Disord       Date:  2018-05-10       Impact factor: 2.298

10.  Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.

Authors:  T M Hommels; R S Hermanides; B Berta; E Fabris; G De Luca; E H Ploumen; C von Birgelen; E Kedhi
Journal:  Cardiovasc Diabetol       Date:  2020-10-02       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.